Comparative Pharmacology
Head-to-head clinical analysis: ADHANSIA XR versus DEXEDRINE SPANSULE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADHANSIA XR versus DEXEDRINE SPANSULE.
ADHANSIA XR vs DEXEDRINE SPANSULE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adhansia XR is a central nervous system (CNS) stimulant. The mechanism of action in attention deficit hyperactivity disorder (ADHD) is not fully known, but it is thought to involve blockade of norepinephrine and dopamine reuptake into presynaptic neurons, increasing their levels in the synaptic cleft. This enhances attention and reduces impulsivity.
Dextroamphetamine is a central nervous system (CNS) stimulant that increases synaptic concentrations of norepinephrine and dopamine by blocking their reuptake and promoting release from presynaptic terminals.
Methylphenidate hydrochloride extended-release: Oral, 18-72 mg once daily in the morning.
5-60 mg orally once daily in the morning, using extended-release capsules.
None Documented
None Documented
Mean terminal elimination half-life is 7.5 hours (range 5-10 hours) following oral administration, allowing twice-daily dosing.
Terminal elimination half-life is 6-8 hours in adults, 10-13 hours in children, and prolonged in alkaline urine (up to 16-20 hours) due to enhanced tubular reabsorption. In hepatic impairment, half-life may extend to 12-15 hours. Steady-state is reached within 2-3 days.
Primarily renal (78% as unchanged drug), with 10% biliary/fecal elimination.
Renal excretion of unchanged drug (approximately 30-40% unchanged) and hepatic metabolism to inactive metabolites (primarily hippuric acid, benzoic acid, and hydroxylated derivatives). About 90% of a dose is excreted in urine within 48 hours, with 10-15% as unchanged dextroamphetamine; minor biliary/fecal elimination (<5% total).
Category C
Category C
CNS Stimulant
CNS Stimulant